Replies to post #13624 on Calmare Therapeutics Inc (fka CTTC)

[Bigspirit1]

You make some good points Powderbum,but I am not nearly as confident as you are.

First of all look at the track record of the JD/MD that was hired. My sources tell me that she has had problems with her license and also with the law concerning drug distribution. I have not spent the time needed to verify but knowing that she previously worked with Conrad, I don't doubt it.

Now lets talk about Conrad. He has a track record of promising it will get better next month, next quarter or next year. He always says he will do something but his delivery record leaves a lot to be desired. When Conrad says "Trust Me" I take it as a curse. Remember from the conference call before the last one, he also promised the flow of revenues from the GSA would be starting "next month". He has lost all credibility in my mind.

Unless I am mistaken I thought that the greatest chunk of the fundraising came from a patient that Dr. treated. While still good, this in itself does not appear to be a testimonial for Conrad's ability to raise funds.

I just happened to read a posting from this board from 2010. Despite having a wonderful product, we have made negative progress over the last 6 years. Smells like a management problem.

No, it is not all Conrad. Who vetted him and who hired him?

[mog1962]

All your arguments seem valid when taken at face value, but you have owned this company long enough to know that this is not the case.

After living through all of Mir's predecessors, it becomes clear that just having a good story has never been enough. If that were the case, the trials would have been completed years ago and sales would have zoomed.

While Mir can raise money, it appears this has been accomplished by issuing shares and diluting the value for those who have held on.He bragged about getting price from teens to nearly fifty cents upon arrival but never says a word now that is hovers on either side of twenty cents.

As to the JD-MD, maybe she has a guaranteed contract that pays her out of the sales of shares and she has no long-term goal to stay on. People no longer have any loyalty to their employers and you should not assume she is in it for anything more than experience and resume padding at a decent, even if short-term salary.

As to trials and needed efficacy, recall that we were told on numerous occasions that trials were underway, that trisl were completed, etc. and that approvals were soon to occur. Then we heard that the codes, etc were rejected for various reasons, and so on..... Needless to say, we seem to be back to where we were when Nano was around with little to show for the time but a lower share price, a well-compensated CEO who remains mum as much as possible, numerous lawsuits hanging over the company, and, form ost shareholders a great opportunity for tax losses.